Real-time Estimate
Cboe BZX
11:15:34 2024-05-23 am EDT
5-day change
1st Jan Change
2.035
USD
+0.74%
-6.84%
+1.80%
Presentation Operator MessageOperator (Operator)Good day, and thank you for standing by. Welco...
This article is reserved for subscribers
Signed up already?
Log In Not subscribed yet?
Subscribe
Earnings Flash (SEER) SEER Posts Q1 Revenue $3.1M, vs. Street Est of $3.8M
May. 08
MT
Transcript : Seer, Inc., Q1 2024 Earnings Call, May 08, 2024
May. 08
Seer, Inc. announces an Equity Buyback for $25 million worth of its shares.
May. 08
CI
Seer, Inc. Provides Revenue Guidance for the Full Year 2024
May. 08
CI
Seer, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
May. 08
CI
Seer, Inc. Launches New Technology Access Center in Europe to Expand Accessibility to Unbiased Proteomic Solutions
May. 08
CI
Seer, Inc. authorizes a Buyback Plan.
May. 02
CI
Transcript : Seer, Inc., Q4 2023 Earnings Call, Feb 29, 2024
Feb. 29
Seer, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
Feb. 29
CI
Seer, Inc. Provides Revenue Guidance for the Full Year 2024
Feb. 29
CI
Earnings Flash (SEER) SEER Reports Q4 Revenue $4.4M, vs. Street Est of $4.05M
Feb. 29
MT
Transcript : Seer, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 03:00 PM
Jan. 10
Seer, Inc. Announces Board and Committee Changes
Dec. 22
CI
Seer, Inc. Announces Management Changes
Nov. 17
CI
Transcript : Seer, Inc., Q3 2023 Earnings Call, Nov 07, 2023
Nov. 07
Seer, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Nov. 07
CI
Earnings Flash (SEER) SEER Posts Q3 Revenue $4.2M, vs. Street Est of $4.3M
Nov. 07
MT
Seer, Inc. Provides Revenue Guidance for the Year 2023
Nov. 07
CI
Seer Inc. Announces Addition of Panome Bio to Centers of Excellence Program
Nov. 01
CI
Transcript : Seer, Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-13-2023 12:15 PM
23-09-13
Earnings Flash (SEER) SEER Posts Q2 Revenue $4M, vs. Street Est of $5.1M
23-08-08
MT
Transcript : Seer, Inc., Q2 2023 Earnings Call, Aug 08, 2023
23-08-08
Seer, Inc. Revises Revenue Guidance for the Full Year 2023
23-08-08
CI
Seer, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
23-08-08
CI
Seer, Inc. Announces the Resignation of Mostafa Ronaghi as Member of the Company's Board of Directors
23-07-21
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Seer, Inc. is a life sciences company. The Company is engaged in developing transformative products that open a new gateway to the proteome. Its product, the Proteograph Product Suite (Proteograph), leverages its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid and large-scale access to the proteome. The Proteograph Product Suite is an integrated solution that includes consumables, an automation instrument and software. Its proprietary engineered NPs provide unbiased sampling of intact proteins across the dynamic range of the proteome, capturing molecular information at the peptide-level, including protein variants. It is focused on driving the adoption of the Proteograph by customers in the proteomics and genomics markets. The Proteograph Product Suite is an integrated solution consisting of consumables, an automation instrument, and software to perform biased, deep proteomic analysis at scale in a matter of hours.
More about the company
Last Close Price
2.02
USD
Average target price
7
USD
Spread / Average Target
+246.53%
Consensus
1st Jan change
Capi.
+1.80% 131M +7.81% 8.06B -3.32% 4.7B -4.55% 2.98B +10.24% 2.14B -28.74% 1.09B +11.38% 1.04B +2.36% 901M -22.90% 757M -53.97% 728M
Scientific & Precision Equipment
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1